An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
Authors:
- Aurelia NoskeANAurelia Noske
- Michael SchwabeMSMichael Schwabe
- Wilko WeichertWWWilko Weichert
- Silvia Darb-EsfahaniSDSilvia Darb-Esfahani
- Ann-Christin BuckendahlABAnn-Christin Buckendahl
- Jalid SehouliJSJalid Sehouli
- Elena I BraicuEBElena I Braicu
- Jan BudcziesJBJan Budczies
- Manfred DietelMDManfred Dietel
- Carsten DenkertCDCarsten Denkert
Open Access
- 14 July 2011
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 1-8
Abstract
In ovarian cancer, the reported rate of EGFR expression varies between 4-70% depending on assessment method and data on patient outcome are conflicting. Methods: In this study we investigated EGFR expression and its prognostic value in a cohort of 121 invasive ovarian carcinomas, using a novel antibody against the intracellular domain of the receptor. We further evaluated an association between EGFR, the nuclear transporter CRM1 as well as COX-2. Furthermore, we evaluated EGFR expression in ten ovarian cancer cell lines and incubated cancer cells with Leptomycin B, a CRM1 specific inhibitor. We observed a membranous and cytoplasmic EGFR expression in 36.4% and 64% of ovarian carcinomas, respectively. Membranous EGFR was an independent prognostic factor for poor overall survival in ovarian cancer patients (HR 2.7, CI 1.1-6.4, p = 0.02) which was also found in the serous subtype (HR 4.6, CI 1.6-13.4, p = 0.004). We further observed a significant association of EGFR with COX-2 and nuclear CRM1 expression (chi-square test for trends, p = 0.006 and p = 0.013, respectively). In addition, combined membranous EGFR/COX-2 expression was significantly related to unfavorable overall survival (HR 7.2, CI 2.3-22.1, p = 0.001). In cell culture, we observed a suppression of EGFR protein levels after exposure to Leptomycin B in OVCAR-3 and SKOV-3 cells. Our results suggest that the EGFR/COX-2/CRM1 interaction might be involved in progression of ovarian cancer and patient prognosis. Hence, it is an interesting anti-cancer target for a combination therapy. Further studies will also be needed to investigate whether EGFR is also predictive for benefit from EGFR targeted therapies.Keywords
This publication has 27 references indexed in Scilit:
- Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future ChallengesJournal of Oncology, 2009
- The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancerBritish Journal of Cancer, 2008
- Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancerCancer, 2008
- EGFR Activation Results in Enhanced Cyclooxygenase-2 Expression through p38 Mitogen-Activated Protein Kinase–Dependent Activation of the Sp1/Sp3 Transcription Factors in Human GliomasCancer Research, 2007
- Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian CancerClinical Cancer Research, 2005
- „IMO” - Intraoperatives Mapping des OvarialkarzinomsZentralblatt Fur Gynakologie, 2003
- Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian CarcinomaThe American Journal of Pathology, 2002
- Toward the Development of a Universal Grading System for Ovarian Epithelial CarcinomaGynecologic Oncology, 1998
- Exportin 1 (Crm1p) Is an Essential Nuclear Export FactorCell, 1997
- Activation of mTOR in a subgroup of ovarian carcinomas: Correlation with p-eIF-4E and prognosisOncology Reports, 1994